Biogen Profit Beats Street Estimates as Cost-Cutting Takes Hold
(Bloomberg) — Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug Leqembi gained traction and cost cuts took hold. Adjusted...
Read more